牛牛AI助理已提取核心訊息
180 Life Sciences Corp. has announced a 1-for-19 reverse stock split of its common stock, effective as of 12:01 A.M. Eastern Time on February 28, 2024. The reverse stock split was approved by the company's Board of Directors following authorization from the company's stockholders to amend the Second Amended and Restated Certificate of Incorporation. This move aims to comply with the Nasdaq's minimum bid price requirement for continued listing on the Nasdaq Capital Market. Prior to the split, the company's common stock was trading below the Nasdaq's minimum $1.00 requirement. The reverse stock split will reduce the number of outstanding shares from approximately 11.3 million to approximately 0.6 million. No fractional shares will be issued; stockholders who would have received a...Show More
180 Life Sciences Corp. has announced a 1-for-19 reverse stock split of its common stock, effective as of 12:01 A.M. Eastern Time on February 28, 2024. The reverse stock split was approved by the company's Board of Directors following authorization from the company's stockholders to amend the Second Amended and Restated Certificate of Incorporation. This move aims to comply with the Nasdaq's minimum bid price requirement for continued listing on the Nasdaq Capital Market. Prior to the split, the company's common stock was trading below the Nasdaq's minimum $1.00 requirement. The reverse stock split will reduce the number of outstanding shares from approximately 11.3 million to approximately 0.6 million. No fractional shares will be issued; stockholders who would have received a fractional share will receive one whole share instead. The company's common stock will continue to trade on Nasdaq under the symbol 'ATNF'. In related news, the company has also reported the exercise of pre-funded warrants resulting in the issuance of 1,111,878 shares of common stock. Additionally, a judge has granted a Motion for Partial Summary Judgment in favor of 180 Life Sciences in a lawsuit involving the company's insurance carriers, which may lead to the advancement of defense costs related to SEC subpoenas.
180 生命科學公司宣佈對普通股進行1比19的反向分割，自美國東部時間2024年2月28日凌晨 12:01 起生效。在公司股東授權修改第二經修訂和重述的公司註冊證書後，公司董事會批准了反向股票拆分。此舉旨在遵守納斯達克繼續在納斯達克資本市場上市的最低出價要求。拆分之前，該公司的普通股交易價格低於納斯達克最低1.00美元的要求。反向股票拆分將使已發行股票的數量從約1130萬股減少到約60萬股。不會發行零碎股票；本來可以獲得部分股份的股東將獲得整股。該公司的普通股將繼續在納斯達克上市，股票代碼爲 “ATNF”。在相關新聞中，該公司還報告了行使預先注資的認股權證，導致發行了1,111,878股普通股。此外，在涉及180生命科學公司的訴訟中，法官批准了部分即決判決的動議，該動議可能導致與美國證券交易委員會傳票相關的辯護費用增加。
180 生命科學公司宣佈對普通股進行1比19的反向分割，自美國東部時間2024年2月28日凌晨 12:01 起生效。在公司股東授權修改第二經修訂和重述的公司註冊證書後，公司董事會批准了反向股票拆分。此舉旨在遵守納斯達克繼續在納斯達克資本市場上市的最低出價要求。拆分之前，該公司的普通股交易價格低於納斯達克最低1.00美元的要求。反向股票拆分將使已發行股票的數量從約1130萬股減少到約60萬股。不會發行零碎股票；本來可以獲得部分股份的股東將獲得整股。該公司的普通股將繼續在納斯達克上市，股票代碼爲 “ATNF”。在相關新聞中，該公司還報告了行使預先注資的認股權證，導致發行了1,111,878股普通股。此外，在涉及180生命科學公司的訴訟中，法官批准了部分即決判決的動議，該動議可能導致與美國證券交易委員會傳票相關的辯護費用增加。
有用
沒用